Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$89.38
-0.3%		$80.47
$54.11
▼
$92.59
$33.73B1.425.15 million shs175,952 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$530.65
-1.5%		$559.10
$518.55
▼
$769.98
$41.77B1.54576,385 shs62,634 shs
ResMed Inc. stock logo
RMD
ResMed
$228.57
-1.0%		$214.34
$180.26
▼
$284.87
$32.95B0.771.31 million shs104,568 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$28.64
-0.1%		$30.17
$28.48
▼
$38.79
$12.03B0.551.24 million shs579,297 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-0.50%+0.82%+2.73%+23.56%+20.71%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-1.13%-2.61%-5.08%-4.56%-15.71%
ResMed Inc. stock logo
RMD
ResMed
-0.26%-1.99%+7.39%+19.01%-14.71%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.05%-2.20%-11.04%-7.17%-22.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$89.38
-0.3%		$80.47
$54.11
▼
$92.59
$33.73B1.425.15 million shs175,952 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$530.65
-1.5%		$559.10
$518.55
▼
$769.98
$41.77B1.54576,385 shs62,634 shs
ResMed Inc. stock logo
RMD
ResMed
$228.57
-1.0%		$214.34
$180.26
▼
$284.87
$32.95B0.771.31 million shs104,568 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$28.64
-0.1%		$30.17
$28.48
▼
$38.79
$12.03B0.551.24 million shs579,297 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
-0.50%+0.82%+2.73%+23.56%+20.71%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-1.13%-2.61%-5.08%-4.56%-15.71%
ResMed Inc. stock logo
RMD
ResMed
-0.26%-1.99%+7.39%+19.01%-14.71%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-1.05%-2.20%-11.04%-7.17%-22.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$88.71-0.75% Downside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.60
Moderate Buy$747.0040.77% Upside
ResMed Inc. stock logo
RMD
ResMed
2.38
Hold$240.315.14% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.91
Reduce$30.937.96% Upside

Current Analyst Ratings Breakdown

Latest SNN, IDXX, DXCM, and RMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
8/31/2026
ResMed Inc. stock logo
RMD
ResMed
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$255.00 ➝ $267.00
8/31/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
8/27/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/19/2026
ResMed Inc. stock logo
RMD
ResMed
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$230.00
8/11/2026
DexCom, Inc. stock logo
DXCM
DexCom
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
ResMed Inc. stock logo
RMD
ResMed
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/11/2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$800.00 ➝ $710.00
8/7/2026
ResMed Inc. stock logo
RMD
ResMed
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$213.00
8/7/2026
ResMed Inc. stock logo
RMD
ResMed
KeyCorp logo
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$260.00 ➝ $255.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.97B6.79$2.75 per share32.56$6.95 per share12.86
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$4.55B9.18$14.68 per share36.14$20.47 per share25.92
ResMed Inc. stock logo
RMD
ResMed
$5.65B5.83$12.78 per share17.89$45.65 per share5.01
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$6.16B1.95$3.39 per share8.45$12.34 per share2.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5335.3329.021.5120.12%35.94%14.75%10/29/2026 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$1.06B$14.2237.2931.932.9125.03%71.96%33.60%11/2/2026 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.52B$10.4321.9017.451.4526.94%25.58%18.89%10/29/2026 (Estimated)
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$625MN/AN/A12.041.07N/AN/AN/AN/A

Latest SNN, IDXX, DXCM, and RMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q4 2026
ResMed Inc. stock logo
RMD
ResMed
$2.89$2.95+$0.06$2.64$1.46 billion$1.46 billion
8/4/2026Q2 2026
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.94$4.27+$0.33$4.27$1.20 billion$1.22 billion
7/30/2026Q2 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6110$0.70+$0.0890$0.64$1.29 billion$1.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.641.14%+9.00%25.31%13 Years
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.933.24%N/AN/AN/A

Latest SNN, IDXX, DXCM, and RMD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2026
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.31202.05%10/2/202610/2/202611/6/2026
8/6/2026
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.661.15%8/20/20268/20/20269/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.47
1.73
1.43
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.19
1.17
0.87
ResMed Inc. stock logo
RMD
ResMed
0.06
3.10
2.42
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.62
2.14
1.11

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
ResMed Inc. stock logo
RMD
ResMed
54.98%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.79%
ResMed Inc. stock logo
RMD
ResMed
0.65%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000377.36 million376.30 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
11,00078.78 million78.16 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
11,370144.25 million143.31 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
16,988419.93 million415.73 millionOptionable

Recent News About These Companies

Jupiter Topco LLC Invests $3.15 Million in Smith & Nephew SNATS, Inc. $SNN
September 3 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-invests-315-million-in-smith-nephew-snats-inc-snn-2026-09-03/
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
September 2 at 9:14 AM  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1097982?snapi
Smith & Nephew SNATS (NYSE:SNN) Downgraded to "Equal Weight" Rating by Morgan Stanley
September 2 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-smith-nephew-snats-nyse-snn-downgraded-to-equal-weight-rating-by-morgan-stanley-2026-09-02/
Brokerages Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Target Price at $30.93
September 2 at 1:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997848
Smith & Nephew SNATS (NYSE:SNN) Shares Gap Up - Should You Buy?
September 1 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-smith-nephew-snats-nyse-snn-shares-gap-up-should-you-buy-2026-09-01/
Smith & Nephew SNATS (NYSE:SNN) Sees Unusually-High Trading Volume - Time to Buy?
August 31 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-smith-nephew-snats-nyse-snn-sees-unusually-high-trading-volume-time-to-buy-2026-08-31/
Legal & General Group Plc Acquires New Position in Smith & Nephew SNATS, Inc. $SNN
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-acquires-new-position-in-smith-nephew-snats-inc-snn-2026-08-29/
Hsbc Holdings PLC Purchases New Stake in Smith & Nephew SNATS, Inc. $SNN
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-new-stake-in-smith-nephew-snats-inc-snn-2026-08-28/
Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Average Rating of "Hold" by Brokerages
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-smith-nephew-snats-inc-nyse-snn-given-average-rating-of-hold-by-brokerages-2026-08-28/
Caisse de depot et placement du Quebec Takes Position in Smith & Nephew SNATS, Inc. $SNN
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-caisse-de-depot-et-placement-du-quebec-takes-position-in-smith-nephew-snats-inc-snn-2026-08-28/
555,999 Shares in Smith & Nephew SNATS, Inc. $SNN Bought by The Manufacturers Life Insurance Company
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-555999-shares-in-smith-nephew-snats-inc-snn-bought-by-the-manufacturers-life-insurance-company-2026-08-27/
PDT Partners LLC Takes $4.25 Million Position in Smith & Nephew SNATS, Inc. $SNN
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pdt-partners-llc-takes-425-million-position-in-smith-nephew-snats-inc-snn-2026-08-26/
UBS cuts Smith & Nephew target on competitive threats to three franchises
August 25, 2026  |  proactiveinvestors.co.ukhttps://www.proactiveinvestors.co.uk/companies/news/1097552?snapi
Commerce Bank Makes New Investment in Smith & Nephew SNATS, Inc. $SNN
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-commerce-bank-makes-new-investment-in-smith-nephew-snats-inc-snn-2026-08-25/
BlackRock Inc. Invests $505.32 Million in Smith & Nephew SNATS, Inc. $SNN
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-invests-50532-million-in-smith-nephew-snats-inc-snn-2026-08-25/
Bank of New York Mellon Corp Invests $89.33 Million in Smith & Nephew SNATS, Inc. $SNN
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-8933-million-in-smith-nephew-snats-inc-snn-2026-08-25/
Smith & Nephew SNATS (NYSE:SNN) Rating Increased to Buy at Wall Street Zen
August 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30979079
Wall Street Zen Upgrades Smith & Nephew SNATS (NYSE:SNN) to Buy
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/wall-street-zen-upgrades-smith-nephew-snats-nysesnn-to-buy-2026-08-24/
Quantbot Technologies LP Invests $6.34 Million in Smith & Nephew SNATS, Inc. $SNN
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantbot-technologies-lp-invests-634-million-in-smith-nephew-snats-inc-snn-2026-08-23/
Heartland Advisors Inc. Makes New Investment in Smith & Nephew SNATS, Inc. $SNN
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-heartland-advisors-inc-makes-new-investment-in-smith-nephew-snats-inc-snn-2026-08-23/
Deutsche Bank AG Buys New Position in Smith & Nephew SNATS, Inc. $SNN
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-buys-new-position-in-smith-nephew-snats-inc-snn-2026-08-22/

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$89.38 -0.31 (-0.34%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$530.65 -8.34 (-1.55%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

ResMed stock logo

ResMed NYSE:RMD

$228.57 -2.30 (-1.00%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$28.64 -0.02 (-0.06%)
As of 10:50 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas